← Back to home

SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS

Clinical trials for SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS explained in plain language.

Never miss a new study

Get alerted when new SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS trials appear

Sign up with your email to follow new studies for SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Diabetes drug tested to fight weight gain from schizophrenia medication

Disease control Recruiting now

This study is testing whether adding the diabetes medication empagliflozin can help control weight gain and other metabolic problems caused by the schizophrenia drug olanzapine. It involves 40 adults with schizophrenia who are already taking olanzapine. Participants will receive …

Matched conditions: SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS

Phase: PHASE3 • Sponsor: Tanta University • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS

Get alerted when new SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS trials appear

Diabetes drug tested to fight weight gain from schizophrenia medication